Log In Sign up
The largest database of trusted experimental protocols

Anti pepha2 ser897

Manufactured by Cell Signaling Technology
Visit Supplier

Anti-pEPHA2-Ser897 is a laboratory reagent that specifically detects phosphorylation of the serine 897 residue on the EPHA2 protein. This phospho-specific antibody can be used to assess the activation state of EPHA2 in various experimental systems.

Automatically generated - may contain errors

Lab products found in correlation

Targeting cortactin, by Qiagen (2 mentions) Anti akt, by Cell Signaling Technology (2 mentions) Anti gsk3β, by Cell Signaling Technology (2 mentions) Nupage gel, by Thermo Fisher Scientific (2 mentions) Anti p44 p42 mapk, by Cell Signaling Technology (2 mentions) Anti phospho p44 p42 mapk thr202 tyr204, by Cell Signaling Technology (2 mentions) Anti acly, by Cell Signaling Technology (2 mentions) Anti pakt ser473 thr308, by Cell Signaling Technology (2 mentions) Anti pacly ser544, by Cell Signaling Technology (2 mentions) Anti epha2, by Abcam (2 mentions) Anti p gsk3β ser9, by Cell Signaling Technology (2 mentions) Rnaimax, by Thermo Fisher Scientific (2 mentions) Anti β actin, by Merck Group (2 mentions)

2 protocols using anti pepha2 ser897

1

Western Blotting of Signaling Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were harvested and lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mm EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, and 1 mM sodium orthovanadate in the presence of protease inhibitors). Whole cell protein extracts were denatured and separated in NuPAGE gels (Invitrogen), transferred to nitrocellulose membranes, and probed with primary and horseradish peroxidase-conjugated secondary antibodies. Anti-p44/p42 MAPK (9102: 1:1,000), anti-phospho-p44/p42 MAPK-Thr202/Tyr204 (9106: 1:1,000), anti-AKT (9272: 1:1,000), anti-pAKT-Ser473/Thr308 (9271, 2965: 1:1,000), anti-ACLY (4332: 1:1,000), anti-pACLY-Ser544 (4331: 1:1,000), anti-pGSK3β-Ser9 (5538: 1:1,000), anti-GSK3β(9832:1:1,000) and anti-pEPHA2-Ser897 (6347: 1:1,000) were purchased from Cell Signaling Technology. Other antibodies used are anti-EPHA2 (3625: 1:1,000) from Epitomics and anti-β−ACTIN (A5316:1:5,000) from Sigma. Full scans of western blots are provided in Supplementary Fig. 7. 50 nM siRNA (CACCAGGAGCAUAUCAACAUA) targeting cortactin (Qiagen) was used for transfections with RNAiMax (Invitrogene). Cells were harvested 48 hours post transfection for assessing knockdown efficiency or other follow-up experiments.
Wu X., Renuse S., Sahasrabuddhe N.A., Zahari M.S., Chaerkady R., Kim M.S., Nirujogi R.S., Mohseni M., Kumar P., Raju R., Zhong J., Yang J., Neiswinger J., Jeong J.S., Newman R., Powers M.A., Somani B.L., Gabrielson E., Sukumar S., Stearns V., Qian J., Zhu H., Vogelstein B., Park B.H, & Pandey A. (2014). Activation of diverse signaling pathways by oncogenic PIK3CA mutations. Nature communications, 5, 4961.
+ Open protocol
+ Expand
2

Western Blotting of Signaling Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were harvested and lysed in modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mm EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, and 1 mM sodium orthovanadate in the presence of protease inhibitors). Whole cell protein extracts were denatured and separated in NuPAGE gels (Invitrogen), transferred to nitrocellulose membranes, and probed with primary and horseradish peroxidase-conjugated secondary antibodies. Anti-p44/p42 MAPK (9102: 1:1,000), anti-phospho-p44/p42 MAPK-Thr202/Tyr204 (9106: 1:1,000), anti-AKT (9272: 1:1,000), anti-pAKT-Ser473/Thr308 (9271, 2965: 1:1,000), anti-ACLY (4332: 1:1,000), anti-pACLY-Ser544 (4331: 1:1,000), anti-pGSK3β-Ser9 (5538: 1:1,000), anti-GSK3β(9832:1:1,000) and anti-pEPHA2-Ser897 (6347: 1:1,000) were purchased from Cell Signaling Technology. Other antibodies used are anti-EPHA2 (3625: 1:1,000) from Epitomics and anti-β−ACTIN (A5316:1:5,000) from Sigma. Full scans of western blots are provided in Supplementary Fig. 7. 50 nM siRNA (CACCAGGAGCAUAUCAACAUA) targeting cortactin (Qiagen) was used for transfections with RNAiMax (Invitrogene). Cells were harvested 48 hours post transfection for assessing knockdown efficiency or other follow-up experiments.
Wu X., Renuse S., Sahasrabuddhe N.A., Zahari M.S., Chaerkady R., Kim M.S., Nirujogi R.S., Mohseni M., Kumar P., Raju R., Zhong J., Yang J., Neiswinger J., Jeong J.S., Newman R., Powers M.A., Somani B.L., Gabrielson E., Sukumar S., Stearns V., Qian J., Zhu H., Vogelstein B., Park B.H, & Pandey A. (2014). Activation of diverse signaling pathways by oncogenic PIK3CA mutations. Nature communications, 5, 4961.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!